Collecting Duct Carcinoma of The Kidney: Analysis of 74 Cases From Multiple Centers
Jinchao Chen,Desheng Cai,Kan Gong,Hua Wang,Zongping Wang,Shaoxing Zhu
DOI: https://doi.org/10.21203/rs.3.rs-820893/v1
2021-01-01
Abstract:Abstract ObjectivesCollecting duct carcinoma (CDC) of the kidney is a rare, aggressive histological subtype of renal cell carcinoma (RCC). We aimed to comprehensively describe the nature of the CDC.Materials and MethodsWe retrospectively collected data from 74 patients with CDC from two centers between January 2001 and December 2020. The clinical characteristics, imaging and pathological features, and diagnostic and treatment methods were analyzed. The Kaplan-Meier method was used to calculate overall survival (OS).ResultsThe mean age of the patients was 61.5 years, and 54.1% were males. The most common symptoms were low back pain (39.2%), hematuria (29.7%), and fatigue (14.9%). Computed tomography (CT) was not specific, with 10.8% of the patients diagnosed with urothelial carcinoma and 4.1% with infectious disease. Thirty-two patients had metastasis to the lymph node (32.4%), bone (13.5%) and lung (8.1%) at presentation, while 17.6% had tumor thrombus in the venous system. Twenty-two patients underwent renal biopsy, and 50% of the patients were diagnosed with CDC. Sixty-one renal surgeries were performed, and the pathological median diameter of the CDC was 6.5 cm. Eight patients received immune checkpoint inhibitors (ICIs), and the objective remission rate (ORR) was 50%. The median follow-up time was 16 months, while the median overall survival (OS) was 24.0 months. The Univariate analysis showed that lymph node metastasis, distant metastasis, sarcomatoid differentiation, increasing stage, and absence of renal surgery were predictors of mortality.ConclusionsCDC is highly aggressive. Patients are commonly diagnosed at an advanced stage. Early surgical treatment can improve prognosis. Though there is still a lack of standard treatment, ICIs bring new hope for the treatment of CDC.